Tagged with Vaccines

Saudi Arabia Over the past three years, Sanofi has significantly expanded its presence in the GCC region, launching 40-50 new products, including treatments for rare diseases and advancements in immunology, diabetes management, and vaccines. As Jean-Paul Scheuer explains, this expansion aligns with Sanofi’s goal to become a leading immunology company globally and…

Global The US National Institutes of Health (NIH) is the largest public investor in HIV/AIDS research globally. This means that, as Director of the Division of AIDS (DAIDS) at the NIH’s National Institute of Allergy & Infectious Diseases (NIAID) Dr Carl Dieffenbach oversees a global HIV/AIDS research portfolio of more than…

Global Founded in 1996 to coordinate and promote HIV vaccine development, IAVI has had a major impact across HIV vaccine development efforts, capacity building in low- and middle-income countries, advocacy work, and access initiatives. While there have been several high-profile late-stage failures in HIV vaccine candidate trials, IAVI scientists like Johan…

Saudi Arabia Farrukh Rehan outlines how GSK Saudi Arabia is actively collaborating with the Saudi government to align its initiatives with Vision 2030 and support national healthcare goals. Through strategic partnerships and MoUs, the company ensures the seamless integration of its innovations into the healthcare system, contributing to improved patient access and…

Africa Medicines for Africa’s Lenias Hwenda reflects on Moderna’s recent decision not to go ahead with plans for a vaccine manufacturing facility in Kenya, and why local production remains crucial to building Africa’s healthcare autonomy.   In a turn of events that is both disappointing yet somehow not surprising, Moderna recently…

Global Having been quietly working away on its mRNA platform for years, Moderna stepped into the limelight during the COVID-19 pandemic and became a commercial-stage outfit almost overnight with its vaccine. After generating sales of USD 18.4 billion in 2022, demand for the company’s Spikevax shot, still its only commercialized product…

Africa Nigeria has become the first country to roll out a new meningitis vaccine. The product, a shot able to protect against the five causes of meningococcal meningitis, was developed by the Serum Institute of India (SIIPL) and health equity non-profit PATH. With more meningitis vaccine-based projects in the pipeline, stakeholders…

Saudi Arabia Since joining Moderna as its first ex-US commercial employee in Spring 2020, Dan Staner has played a leading role in developing what is now one of the world’s top 20 biggest pharma companies. Speaking exclusively to PharmaBoardroom, Staner describes how Moderna has been able to fashion a new, optimised company…

Global Gavi, the world’s largest vaccine-focused public-private partnership has a new leader. Pakistani Senator Dr Sania Nishtar has officially assumed the role of CEO following a period of leadership uncertainty for the organisation and must now lay out Gavi’s strategic plan for 2026 to 2030, as well as convince its partners…

Saudi Arabia Halal pharmaceuticals, or medicines produced according to Islamic dietary laws, presented a global market worth some USD 100 billion in 2019, yet much of halal pharmaceuticals’ potential remains untapped. In conversation with PharmaBoardroom, Mazen M. Hassanain, co-founder and managing director of SaudiVax, a pioneer in halal vaccines, discusses the development…

USA The COVID-19 pandemic looked like a turning point for vaccines, but while R&D has made tremendous strides with ground-breaking platform technologies and mRNA, vaccines continue to attract fewer investments than areas such as oncology. As panel members at the “Reviewing Vaccine Pipeline Breakthroughs and Barriers” session during BIO’s recent CEO…

UK Last year the UK-based pharma industry warned against the country’s waning competitiveness, condemning the government’s statutory scheme designed to control drug prices. UK-headquartered AstraZeneca joined the battle cry, claiming it would be choosing Ireland over Britain, a decision the company has now more than revised with a GBP 650 million…